Alex Thompson
Stock Analyst at Stifel
(1.61)
# 3,221
Out of 4,876 analysts
36
Total ratings
46.43%
Success rate
-8.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.76 | +183.51% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $44.12 | +24.66% | 1 | May 20, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $14.78 | +55.67% | 3 | May 2, 2025 | |
| THRD Third Harmonic Bio | Downgrades: Hold | $23 → $5 | $5.43 | -7.92% | 2 | Mar 28, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $4.78 | +653.14% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $29.96 | +100.27% | 1 | Mar 25, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $207 | $172.14 | +20.25% | 2 | Nov 15, 2024 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $11.08 | +342.24% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $560.14 | -10.74% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $15.22 | +254.80% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $44 | $17.63 | +149.57% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.34 | -14.53% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $47.52 | +45.20% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.47 | -31.97% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $14.33 | +179.13% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $8.43 | +3,695.97% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $16.10 | +111.18% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.25 | +2,540.00% | 1 | Dec 14, 2022 |
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.76
Upside: +183.51%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $44.12
Upside: +24.66%
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $14.78
Upside: +55.67%
Third Harmonic Bio
Mar 28, 2025
Downgrades: Hold
Price Target: $23 → $5
Current: $5.43
Upside: -7.92%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $4.78
Upside: +653.14%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $29.96
Upside: +100.27%
Ascendis Pharma
Nov 15, 2024
Maintains: Buy
Price Target: $200 → $207
Current: $172.14
Upside: +20.25%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $11.08
Upside: +342.24%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $560.14
Upside: -10.74%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $15.22
Upside: +254.80%
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $17.63
Upside: +149.57%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.34
Upside: -14.53%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $47.52
Upside: +45.20%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.47
Upside: -31.97%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $14.33
Upside: +179.13%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $8.43
Upside: +3,695.97%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $16.10
Upside: +111.18%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.25
Upside: +2,540.00%